LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

Strona główna・Stock List・Coherus Oncology Inc

Coherus Oncology Inc

Open

SectorHealthcare

1.47 -2

Buy Sell

Overview

Share price change

24h

Current

Min

1.45

Max

1.5

Key metrics
By Trading Economics
Income	-280M -38M
Sales	-438K 12M
P/E Sector Avg	3.509 51.415
Profit margin	-311.348
Employees	147
EBITDA	7.1M -36M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+425.48% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	33M 292M
Previous open	3.47
Previous close	1.47

News Sentiment

By Acuity

50%

157 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

0.9209 / 1.05 Support & Resistance

Coherus Oncology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 maj 2026, 23:10 UTC

Hot Stocks

Stocks to Watch: Agilysys, XP

18 maj 2026, 18:44 UTC

Major Market Movers

Claritev Shares Recover After Comments About DOJ

18 maj 2026, 23:55 UTC

Earnings

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 maj 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 maj 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 maj 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 maj 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 maj 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 maj 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 maj 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 maj 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 maj 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

18 maj 2026, 20:25 UTC

Earnings

Correct: XP 1Q Total Client Assets BRL1.53T

18 maj 2026, 20:23 UTC

Earnings

XP 1Q Total Client Assets BRL1.53B

18 maj 2026, 20:19 UTC

Earnings

XP 1Q Adj EPS BRL2.49 >XP

18 maj 2026, 20:19 UTC

Earnings

XP 1Q Rev BRL4.73B >XP

18 maj 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 maj 2026, 19:00 UTC

Earnings

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 maj 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 maj 2026, 18:17 UTC

Market Talk

Acquisitions, Mergers, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 maj 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 maj 2026, 16:57 UTC

Acquisitions, Mergers, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 maj 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 maj 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 maj 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 maj 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 maj 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 maj 2026, 16:49 UTC

Acquisitions, Mergers, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 maj 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Vinci Buys Canada's Modern Group of Companies

Peer Comparison

Price change

Coherus Oncology Inc Forecast

Price Target

By TipRanks

425.48% upside

12 Months Forecast

Average 8.25 USD 425.48%

High 12 USD

Low 4 USD

Based on 5 Wall Street analysts offering 12 month price targets forCoherus Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Coherus Oncology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9209 / 1.05Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

157 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.